Status:
RECRUITING
Atrial Fibrillation in Active Cancer Patients
Lead Sponsor:
University Hospital, Caen
Collaborating Sponsors:
University Hospital, Marseille, France
Hospices Civils de Lyon, France
Conditions:
Cancer
Drug Toxicity
Eligibility:
All Genders
18+ years
Brief Summary
Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and c...
Eligibility Criteria
Inclusion
- adult patients
- outpatients or hospitalized patients
- with a confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral metastases, or acute leukemia) and an active cancer (defined as cancer that had been diagnosed within the past 6 months or recurrent locally advanced or metastatic cancer, for which anticancer treatment was being given at the time of enrollment or during 6 months before enrollment)
- at least 1 episode of atrial fibrillation (new onset AF occuring after cancer diagnosis or history of paroxysmal of persistant AF prior to cancer diagnosis and an AF recurrence after cancer diagnosis)
- in sinus rhythm at the time of cancer diagnosis
Exclusion
- patient with palliative cares or other conditions resulting in short term death (death expected in the month following atrial fibrillation occurrence)
- history of long-standing persistant or permanent AF prior to cancer diagnosis
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04696081
Start Date
September 1 2021
End Date
January 1 2026
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandre
Caen, Normandy, France, 14000